治疗恶性胶质瘤的CAR T细胞开发临床进展
本文综述了CAR T细胞治疗恶性胶质瘤(如胶质母细胞瘤和弥漫性中线胶质瘤)的临床进展,重点介绍了靶向IL-13Rα2、HER2、EGFR、EGFRvIII、EphA2、GD2和B7-H3等肿瘤相关抗原的临床试验,讨论了抗原下调、CAR T细胞持久性有限等障碍,以及多抗原靶向、替代细胞来源和给药途径创新等新兴策略。
要点
- CAR T细胞治疗血液肿瘤的成功尚未能转化至恶性胶质瘤,受多种生物学、解剖学和免疫学因素限制。
- 早期研究确立了抗原特异性CAR T细胞靶向的概念验证,但抗原下调和CAR T细胞持久性有限仍是重要障碍。
- 多抗原靶向、替代细胞来源和给药途径创新等新方法为克服挑战提供了有前景的策略。
核心结论
- 研究性CAR T细胞疗法的快速发展预示着胶质瘤治疗未来的巨大潜力。
- 未来研究需要优化抗原靶向策略、优化CAR T细胞持久性并整合联合方法,以充分发挥该模式的治疗潜力并改善针对脑肿瘤的治疗窗口。
研究设计与样本
- 本文为综述,总结了过去十年中部署的CAR T细胞治疗胶质瘤的历史和正在进行的临床试验。
主要发现
- 早期研究确立了抗原特异性CAR T细胞靶向的概念验证。
- 免疫逃逸机制如抗原下调和有限的CAR T细胞持久性仍是显著障碍。
- 多抗原靶向、替代细胞来源和给药途径创新等新方法提供了有前景的策略。
局限性
- 免疫逃逸机制如抗原下调和有限的CAR T细胞持久性仍是显著障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Chimeric antigen receptor (CAR) T cell therapy is an exciting modality of immunotherapy that has revolutionized the treatment of hematologic malignancies. However, translating this success to malignant gliomas such as glioblastoma (GBM) and diffuse midline glioma (DMG) remains a formidable challenge due to multiple biologic, anatomic, and immunologic factors. Despite these hurdles, a number of clinical trials deployed over the last decade have increased optimism for the potential of CAR T cell therapy in glioma treatment. EVIDENCE SYNTHESIS: We highlight historical and ongoing clinical trials of CAR T cell therapy in glioma, with a focus on key tumor-associated antigens such as IL-13Rα2, HER2, EGFR, EGFRvIII, EphA2, GD2, and B7-H3. Early studies established proof-of-concept for antigen-specific CAR T cell targeting, yet immune evasion mechanisms such as antigen downregulation and limited CAR T cell persistence remain significant obstacles. Recent approaches, including multiantigen targeting, alternative cell sources, and innovations in delivery routes offer promising strategies to overcome these challenges. CONCLUSIONS: The rapid evolution of investigational CAR T cell therapies portends great potential for the future of glioma treatment. Future studies will need to refine antigen targeting strategies, optimize CAR T cell persistence, and integrate combinatorial approaches to fully harness the therapeutic potential of this modality and improve the therapeutic window against brain tumors.
引用
- Grewal EP, Nahed BV, Carter BS, et al. Clinical progress in the development of CAR T cells to treat malignant glioma. J Neurooncol. 2024. PMID: 39695004. doi:10.1007/s11060-024-04909-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。